These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 15894249)

  • 1. Current status and future promise of pharmacotherapeutic strategies for Alzheimer's disease.
    Standridge JB
    J Am Med Dir Assoc; 2005; 6(3):194-9. PubMed ID: 15894249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status and future promise of pharmacotherapeutic strategies for Alzheimer's disease.
    Standridge JB
    J Am Med Dir Assoc; 2006 Mar; 7(3 Suppl):S46-51, 45. PubMed ID: 16500279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
    Standridge JB
    Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapeutic approaches to the prevention of Alzheimer's disease.
    Standridge JB
    Am J Geriatr Pharmacother; 2004 Jun; 2(2):119-32. PubMed ID: 15555488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
    Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
    J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Memantine brakes Alzheimer's dementia. The NMDA antagonist is effective in severe cases, too].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():21. PubMed ID: 14579479
    [No Abstract]   [Full Text] [Related]  

  • 8. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
    Farlow MR; Alva G; Meng X; Olin JT
    Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of increasing donepezil in mild to moderate Alzheimer's disease patients who show a diminished response to 5 mg donepezil: a preliminary study.
    Yatabe Y; Hashimoto M; Kaneda K; Honda K; Ogawa Y; Yuuki S; Ikeda M
    Psychogeriatrics; 2013 Jun; 13(2):88-93. PubMed ID: 23909965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Navigating patients and caregivers through the course of Alzheimer's disease.
    Aupperle PM
    J Clin Psychiatry; 2006; 67 Suppl 3():8-14; quiz 23. PubMed ID: 16649846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease.
    Gauthier S; Molinuevo JL
    Alzheimers Dement; 2013 May; 9(3):326-31. PubMed ID: 23110864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical treatment of Alzheimer's disease: past, present, and future.
    Ott BR
    Med Health R I; 2002 Jul; 85(7):210-2. PubMed ID: 12182092
    [No Abstract]   [Full Text] [Related]  

  • 14. Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.
    Hatoum HT; Thomas SK; Lin SJ; Lane R; Bullock R
    J Med Econ; 2009 Jun; 12(2):98-103. PubMed ID: 19492974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memantine for treatment of moderate to severe Alzheimer's disease.
    Perras C
    Issues Emerg Health Technol; 2005 Mar; (64):1-4. PubMed ID: 15762015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic.
    Riordan KC; Hoffman Snyder CR; Wellik KE; Caselli RJ; Wingerchuk DM; Demaerschalk BM
    Neurologist; 2011 Mar; 17(2):121-3. PubMed ID: 21364371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease.
    Prescrire Int; 2003 Dec; 12(68):203-5. PubMed ID: 14986682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.